Dogwood Therapeutics, Inc. (DWTX) Discusses Halneuron and Pipeline Advances for Chemotherapy

Dogwood Therapeutics, Inc. (DWTX) Discusses Halneuron and Pipeline Advances for Chemotherapy-Induced Neuropathic Pain September 1, 2026 10:00 AM EDT Company Participants Greg Duncan - Chairman & CEO Iain Dukes R. Gendreau - Chief Medical Officer Conference Call Participants Mark Joyce Jerry Evarts Jason Mccarthy - Maxim Group LLC, Research Division Xun Lee - H.C. Wainwright & Co, LLC, Research Division Daniel Ferry - Lifesci Advisors, LLC Presentation Operator Good morning, everyone, and welcome to the Dogwood Therapeutics Virtual KOL event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Dogwood website following the conclusion of the event. I'd now like to turn the call over to Greg Duncan, Chief Executive Officer and Chairman of the Board of Directors at Dogwood Therapeutics. Please go ahead, Greg. Greg Duncan Chairman & CEO Thank you very much, Tara, and welcome to everybody attending this morning's presentation. We're delighted to share why we're so excited about Halneuron as a potential new treatment for patients who are suffering from chemotherapy-induced neuropathic pain. For those of you who are new to the Dogwood story, Dogwood is a clinical stage biotech company. We are focused on novel new treatments for both pain and neuropathy. We believe our approach is further differentiated given our focus on cancer and chemotherapy-related pain. We have 2 assets in the pipeline. We'll spend most of the time today on Halneuron, which is a NaV1.7 inhibitor, but we also have SP16, an LRP1 agonist, which is poised to go into development as adjunctive therapy alongside chemotherapy to prevent emerging to neuropathy during chemotherapy treatment. The trial will likely dose patients in the second half of this year, and the trial is fully funded by the National Cancer Institute based on very exciting preclinical data supporting the program.